Abstract
A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have